Showing results (11-20 of 27) with videos related to
Sort By:
Pageof 3
Journal of Translational Medicine|July 24, 2025
T cell-engaging CD276xCD3 bispecific antibody for treatment of endometrial cancerS M Greiner, J Mauermann, M S Lutz, et al.Clinical and Experimental Immunology|April 12, 2020
Monocyte-derived dendritic cells display a highly activated phenotype and altered function in patients with familial Mediterranean feverT Funk, A R Fuchs, V S Altdörfer, et al.Journal of Immunology (Baltimore, Md. : 1950)|August 18, 2000
Constitutive expression of functional 4-1BB (CD137) ligand on carcinoma cellsH R Salih, S G Kosowski, V F Haluska, et al.Leukemia|August 6, 2014
Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapyC Berlin, D J Kowalewski, H Schuster, et al.Blood Cancer Journal|April 9, 2016
Carfilzomib alters the HLA-presented peptidome of myeloma cells and impairs presentation of peptides with aromatic C-terminiD J Kowalewski, S Walz, L Backert, et al.Leukemia|July 21, 2016
An Fc-optimized CD133 antibody for induction of NK cell reactivity against myeloid leukemiaS P Koerner, M C André, J S Leibold, et al.Leukemia|February 1, 2012
Generation, selection and preclinical characterization of an Fc-optimized FLT3 antibody for the treatment of myeloid leukemiaM Hofmann, L Große-Hovest, T Nübling, et al.Leukemia|September 13, 2017
Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemiaK Reiter, H Polzer, C Krupka, et al.European Journal of Cancer (Oxford, England : 1990)|October 22, 2017
Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantationS K Metzelder, T Schroeder, M Lübbert, et al.Leukemia|July 26, 2012
EVI-1 modulates leukemogenic potential and apoptosis sensitivity in human acute lymphoblastic leukemiaM Konantz, M C André, M Ebinger, et al.Pageof 3